Evidence map›Paper›PMID 39251672›Full record

ArticleScientific reports2024

New insight into primary hyperparathyroidism using untargeted metabolomics.

Marta Wielogórska-Partyka, Joanna Godzien, Beata Podgórska-Golubiewska, Julia Sieminska, Maricruz Mamani-Huanca, Karolina Mocarska, Marta Stępniewska, Jakub Supronik, Bartosz Pomichter, Angeles Lopez-Gonzalvez and 9 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Metabolomics in Endocrinology: The Way Forward.Indian journal of endocrinology and metabolism
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Marta Wielogórska-PartykaDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Joanna GodzienMetabolomics and Proteomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Skłodowskiej 24a, 15-276, Białystok, Poland. joanna.godzien@umb.edu.pl.ORCID 0000-0002-9477-057X
Beata Podgórska-GolubiewskaDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Julia SieminskaMetabolomics and Proteomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Skłodowskiej 24a, 15-276, Białystok, Poland.
Maricruz Mamani-HuancaCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Spain.
Karolina MocarskaDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Marta StępniewskaDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Jakub SupronikDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Bartosz PomichterDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Angeles Lopez-GonzalvezCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Spain.
Gabryela KozłowskaClinical Research Centre, Medical University of Bialystok, 15-276, Białystok, Poland.
Angelika BuczyńskaClinical Research Centre, Medical University of Bialystok, 15-276, Białystok, Poland.
Anna Popławska-KitaDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Agnieszka AdamskaDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Małgorzata SzelachowskaDepartment of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Coral BarbasCentro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Spain.
Michal Ciborowski *Metabolomics and Proteomics Laboratory, Clinical Research Centre, Medical University of Bialystok, Skłodowskiej 24a, 15-276, Białystok, Poland.
Katarzyna Siewko *Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.
Adam Krętowski *Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, 15-276, Białystok, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Primary Hyperparathyroidism (PHPT) is characterized by excessive parathormone (PTH) secretion and disrupted calcium homeostasis. Untargeted metabolomics offers a valuable approach to understanding the complex metabolic alterations associated with different diseases, including PHPT. Plasma untargeted metabolomics was applied to investigate the metabolic profiles of PHPT patients compared to a control group. Two complementary liquid-phase separation techniques were employed to comprehensively explore the metabolic landscape in this retrospective, single-center study. The study comprised 28 female patients diagnosed following the current guidelines of PHPT diagnosis and a group of 30 healthy females as a control group. To evaluate their association with PHPT, we identified changes in plasma metabolic profiles in patients with PHPT compared to the control group. The primary outcome measure included detecting plasma metabolites and discriminating PHPT patients from controls. The study unveiled specific metabolic imbalances that may link L-amino acids with peptic ulcer disease, gamma-glutamyls with oxidative stress, and asymmetric dimethylarginine (ADMA) with cardiovascular complications. Several metabolites, such as gamma-glutamyls, caffeine, sex hormones, carnitine, sphingosine-1-phosphate (S-1-P), and steroids, were connected with reduced bone mineral density (BMD). Metabolic profiling identified distinct metabolic patterns between patients with PHPT and healthy controls. These findings provided valuable insights into the pathophysiology of PHPT.

Indexed as

Hyperparathyroidism, PrimaryMetabolomicsAdultAgedAmino AcidsArginineBiomarkersBone DensityCase-Control StudiesFemaleHumansLysophospholipidsMetabolomeMiddle AgedParathyroid HormoneRetrospective StudiesAmino AcidsArginineBiomarkersLysophospholipidsN,N-dimethylarginineParathyroid HormoneSphingosinesphingosine 1-phosphateBone mineral densityCalciumPrimary hyperparathyroidismUntargeted metabolomics

Identifiers

PMID39251672
PMCPMC11385525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.